Exploring nasopharyngeal microbiota profile in children affected by SARS-CoV-2 infection

From BugSigDB
Reviewed Marked as Reviewed by ChiomaBlessing on 2024-5-6
study design
Citation
PMID PubMed identifier for scientific articles.
DOI Digital object identifier for electronic documents.
Authors
Romani L, Del Chierico F, Pane S, Ristori MV, Pirona I, Guarrasi V, Cotugno N, Bernardi S, Lancella L, Perno CF, Rossi P, Villani A, Campana A, Palma P
Journal
Microbiology spectrum
Year
Pages:
First page:
Keywords:
The relationship between COVID-19 and nasopharyngeal (NP) microbiota has been investigated mainly in the adult population. We explored the NP profile of children affected by COVID-19, compared to healthy controls (CTRLs). NP swabs of children with COVID-19, collected between March and September 2020, were investigated at the admission (T0), 72 h to 7 days (T1), and at the discharge (T2) of the patients. NP microbiota was analyzed by 16S rRNA targeted-metagenomics. Data from sequencing were investigated by QIIME 2.0 and PICRUSt 2. Multiple machine learning (ML) models were exploited to classify patients compared to CTRLs. The NP microbiota of COVID-19 patients (N = 71) was characterized by reduction of α-diversity compared to CTRLs (N = 59). The NP microbiota of COVID-19 cohort appeared significantly enriched in Streptococcus, Haemophilus, Staphylococcus, Veillonella, Enterococcus, Neisseria, Moraxella, Enterobacteriaceae, Gemella, Bacillus, and reduced in Faecalibacterium, Akkermansia, Blautia, Bifidobacterium, Ruminococcus, and Bacteroides, compared to CTRLs (FDR < 0.001). Exploiting ML models, Enterococcus, Pseudomonas, Streptococcus, Capnocytopagha, Tepidiphilus, Porphyromonas, Staphylococcus, and Veillonella resulted as NP microbiota biomarkers, in COVID-19 patients. No statistically significant differences were found comparing the NP microbiota profile of COVID-19 patients during the time-points or grouping patients on the basis of high, medium, and low viral load (VL). This evidence provides specific pathobiont signatures of the NP microbiota in pediatric COVID-19 patients, and the reduction of anaerobic protective commensals. Our data suggest that the NP microbiota may have a specific disease-related signature since infection onset without changes during disease progression, regardless of the SARS-CoV-2 VL.

Experiment 1


Reviewed Marked as Reviewed by ChiomaBlessing on 2024-4-8

Curated date: 2024/03/14

Curator: Ndruscilla

Revision editor(s): Ndruscilla, Joan Chuks

Subjects

Location of subjects
United States of America
Host species Species from which microbiome was sampled. Contact us to have more species added.
Homo sapiens
Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
Nasopharynx Nasenrachenraum,Epipharynx,Nasal part of pharynx,Pars nasalis pharyngis,Rhinopharynx,Nasopharynx,nasopharynx
Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
COVID-19 2019 novel coronavirus,2019 novel coronavirus infection,2019-nCoV,2019-nCoV infection,beta-CoV,beta-CoVs,betacoronavirus,coronavirus disease 2019,SARS-coronavirus 2,SARS-CoV-2,severe acute respiratory syndrome coronavirus 2,severe acute respiratory syndrome coronavirus 2 infectious disease,β-coronavirus,β-CoV,β-CoVs,COVID-19,cOVID-19
Group 0 name Corresponds to the control (unexposed) group for case-control studies
healthy controls
Group 1 name Corresponds to the case (exposed) group for case-control studies
COVID-19 patients
Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
Children whose Nasopharyngeal swab were positive for SARS-CoV-2 infection, as assayed by a molecular test.
Group 0 sample size Number of subjects in the control (unexposed) group
59
Group 1 sample size Number of subjects in the case (exposed) group
71
Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)
none

Lab analysis

Sequencing type
16S
16S variable region One or more hypervariable region(s) of the bacterial 16S gene
V3-V4
Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
Illumina

Statistical Analysis

Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
relative abundances
Statistical test
LEfSe
Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
0.05
MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
Yes
LDA Score above Threshold for the linear discriminant analysis (LDA) score for studies using the popular LEfSe tool
2
Matched on Factors on which subjects have been matched on in a case-control study
age

Alpha Diversity

Shannon Estimator of species richness and species evenness: more weight on species richness
decreased
Chao1 Abundance-based estimator of species richness
decreased
Simpson Estimator of species richness and species evenness: more weight on species evenness
decreased
Richness Number of species
decreased
Faith Phylogenetic diversity, takes into account phylogenetic distance of all taxa identified in a sample
decreased

Signature 1

Reviewed Marked as Reviewed by ChiomaBlessing on 2024-5-6

Curated date: 2024/03/14

Curator: Ndruscilla

Revision editor(s): Ndruscilla, Ayibatari, Joan Chuks

Source: Figure 3

Description: Differences in bacterial taxa abundance of nasopharyngeal (NP) microbiota in COVID-19 patients VS Control (CTRL) groups

Abundance in Group 1: increased abundance in COVID-19 patients

NCBI Quality ControlLinks
Anaerolinea
Bacillus
Burkholderia
Burkholderiaceae
Capnocytophaga
Carnobacteriaceae
Chromobacteriaceae
Enterobacteriaceae
Enterococcaceae
Enterococcus
Gemella
Gemellaceae
Gulbenkiania
Haemophilus
Leptotrichia
Leptotrichiaceae
Micrococcaceae
Moraxella
Moraxellaceae
Negativicutes
Neisseria
Prevotella
Prevotellaceae
Rothia
Staphylococcus
Streptococcus
Veillonella
Veillonellaceae

Revision editor(s): Ndruscilla, Ayibatari, Joan Chuks

Signature 2

Reviewed Marked as Reviewed by ChiomaBlessing on 2024-5-6

Curated date: 2024/03/14

Curator: Ndruscilla

Revision editor(s): Ndruscilla, Ayibatari, Joan Chuks

Source: Figure 3

Description: Differences in bacterial taxa abundance of nasopharyngeal (NP) microbiota in COVID-19 patients Vs Control (CTRL) groups

Abundance in Group 1: decreased abundance in COVID-19 patients

NCBI Quality ControlLinks
Agathobacter
Akkermansia
Alistipes
Bacteroidaceae
Bacteroides
Bifidobacteriaceae
Bifidobacterium
Blautia
Christensenellaceae
Faecalibacterium
Frisingicoccus
Lachnospiraceae
Oscillospiraceae
Phascolarctobacterium
Rikenellaceae
Ruminococcus
Subdoligranulum

Revision editor(s): Ndruscilla, Ayibatari, Joan Chuks

Experiment 2


Reviewed Marked as Reviewed by ChiomaBlessing on 2024-5-6

Curated date: 2024/04/11

Curator: Joan Chuks

Revision editor(s): Joan Chuks

Differences from previous experiment shown

Subjects

Group 0 name Corresponds to the control (unexposed) group for case-control studies
NO COVID-19 (Patients with diagnosis different from COVID-19)
Group 0 sample size Number of subjects in the control (unexposed) group
7

Lab analysis

Statistical Analysis

Alpha Diversity

Shannon Estimator of species richness and species evenness: more weight on species richness
unchanged
Chao1 Abundance-based estimator of species richness
unchanged
Simpson Estimator of species richness and species evenness: more weight on species evenness
unchanged
Richness Number of species
unchanged
Faith Phylogenetic diversity, takes into account phylogenetic distance of all taxa identified in a sample
unchanged

Signature 1

Reviewed Marked as Reviewed by ChiomaBlessing on 2024-5-6

Curated date: 2024/04/11

Curator: Joan Chuks

Revision editor(s): Joan Chuks

Source: Figure S4

Description: Differences in bacterial taxa abundance of nasopharyngeal (NP) microbiota in COVID-19 patients Vs NO COVID-19 (Patients with diagnosis different from COVID-19)

Abundance in Group 1: increased abundance in COVID-19 patients

NCBI Quality ControlLinks
Dialister

Revision editor(s): Joan Chuks

Signature 2

Reviewed Marked as Reviewed by ChiomaBlessing on 2024-5-6

Curated date: 2024/04/11

Curator: Joan Chuks

Revision editor(s): Joan Chuks, ChiomaBlessing

Source: Figure S4

Description: Differences in bacterial taxa abundance of nasopharyngeal (NP) microbiota in COVID-19 patients Vs NO COVID-19 (Patients with diagnosis different from COVID-19)

Abundance in Group 1: decreased abundance in COVID-19 patients

NCBI Quality ControlLinks
Alloprevotella
Alphaproteobacteria
Beijerinckiaceae
Fusobacteriaceae
Fusobacterium
Lautropia
Moraxellaceae
Paracoccaceae
Paracoccus
Pseudomonadaceae
Pseudomonadales
Rhodobacterales
Sphingomonadaceae
Sphingomonadales
Sphingomonas
unidentified
Pseudomonas

Revision editor(s): Joan Chuks, ChiomaBlessing